Cargando…
Monoclonal Antibodies Approved for Cancer Therapy
Twenty-four monoclonal antibodies (mAbs) targeted to a total of 16 different antigens are currently approved for the treatment of an increasing number of cancers. Six are directed against antigens expressed on B lymphocytes (ibritumomab tiuxetan, obinutuzumab, ofatumumab, and rituximab to CD20, bren...
Autor principal: | Baldo, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153453/ http://dx.doi.org/10.1007/978-3-319-30472-4_3 |
Ejemplares similares
-
Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
por: Baldo, Brian A.
Publicado: (2022) -
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
por: Baldo, Brian A
Publicado: (2013) -
Side Effects of Cytokines Approved for Therapy
por: Baldo, Brian A.
Publicado: (2014) -
Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections
por: Reichert, Janice M.
Publicado: (2012) -
Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires
por: Petersen, Brian M., et al.
Publicado: (2021)